• Charles River Laboratories International recently reported fourth-quarter and full-year 2025 results, including revenue of US$994.23 million for the quarter, a net loss of US$276.56 million, significant impairment charges, and new 2026 guidance calling for at least flat to 1.5% reported revenue growth and GAAP EPS of US$6.30 to US$6.80.
• Alongside the earnings, the company announced major leadership changes, appointing Glenn G. Coleman as Chief Financial Officer effective April 6, 2026, and creating a new Chief Legal Officer role for Kerry Dailey starting March 30, 2026, signaling an increased focus on financial discipline, governance, and legal risk management.
• We’ll now examine how the stronger-than-expected fourth-quarter performance and 2026 outlook might reshape Charles River’s existing investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Charles River Laboratories International Investment Narrative Recap

To own Charles River Laboratories, you need to believe its contract research and manufacturing services will remain essential as drug development becomes more complex, even as non-animal methods advance. The latest results, with impairments driving a sizeable net loss and only flat to modest 2026 revenue guidance, keep the near term focused on execution: converting backlog into growth and stabilizing margins. These news items do not materially change the primary risk around demand softness and cancellations.

The most relevant update here is the new 2026 guidance for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30 to US$6.80. Coming after heavy impairment charges and a year of losses, this outlook puts more weight on cost discipline, operational improvements, and the incoming CFO and CLO to support financial and governance rigor, all of which tie directly into whether the company can turn cautious demand trends into a more durable earnings recovery.

Yet investors should also be aware that cancellation trends in longer term studies and a book to bill below 1x could still...

Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028. This requires 2.8% yearly revenue growth and an earnings increase of about $552 million from -$69.2 million today.

Uncover how Charles River Laboratories International's forecasts yield a $215.73 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were penciling in revenue of about US$4.5 billion and EPS near US$13.77 by 2028, which is far more upbeat than consensus and assumes faster uptake of new testing approaches. Compared with the baseline focus on backlog risk and flat 2026 growth, this higher bar could be reconsidered in light of the latest impairments and cautious guidance. You should expect that different analysts may adjust their views from here and it is worth weighing several of these perspectives side by side.

Explore 2 other fair value estimates on Charles River Laboratories International - why the stock might be worth as much as 45% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 54 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.